IBDEI0CZ ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5828,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,5829,0)
 ;;=173.81^^28^386^1
 ;;^UTILITY(U,$J,358.3,5829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5829,1,3,0)
 ;;=3^173.81
 ;;^UTILITY(U,$J,358.3,5829,1,4,0)
 ;;=4^BCCA SKIN,SITE NEC
 ;;^UTILITY(U,$J,358.3,5829,2)
 ;;=^340488
 ;;^UTILITY(U,$J,358.3,5830,0)
 ;;=173.82^^28^386^19
 ;;^UTILITY(U,$J,358.3,5830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5830,1,3,0)
 ;;=3^173.82
 ;;^UTILITY(U,$J,358.3,5830,1,4,0)
 ;;=4^SCCA SKIN,SITE NEC
 ;;^UTILITY(U,$J,358.3,5830,2)
 ;;=^340489
 ;;^UTILITY(U,$J,358.3,5831,0)
 ;;=173.89^^28^386^20
 ;;^UTILITY(U,$J,358.3,5831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5831,1,3,0)
 ;;=3^173.89
 ;;^UTILITY(U,$J,358.3,5831,1,4,0)
 ;;=4^SKIN CANCER-OTHER,SITE NEC
 ;;^UTILITY(U,$J,358.3,5831,2)
 ;;=^340490
 ;;^UTILITY(U,$J,358.3,5832,0)
 ;;=174.9^^28^386^3
 ;;^UTILITY(U,$J,358.3,5832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5832,1,3,0)
 ;;=3^174.9
 ;;^UTILITY(U,$J,358.3,5832,1,4,0)
 ;;=4^BREAST CANCER
 ;;^UTILITY(U,$J,358.3,5832,2)
 ;;=^267202
 ;;^UTILITY(U,$J,358.3,5833,0)
 ;;=180.9^^28^386^4
 ;;^UTILITY(U,$J,358.3,5833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5833,1,3,0)
 ;;=3^180.9
 ;;^UTILITY(U,$J,358.3,5833,1,4,0)
 ;;=4^CERVICAL CANCER
 ;;^UTILITY(U,$J,358.3,5833,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,5834,0)
 ;;=183.0^^28^386^16
 ;;^UTILITY(U,$J,358.3,5834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5834,1,3,0)
 ;;=3^183.0
 ;;^UTILITY(U,$J,358.3,5834,1,4,0)
 ;;=4^OVARIAN CANCER
 ;;^UTILITY(U,$J,358.3,5834,2)
 ;;=^267224
 ;;^UTILITY(U,$J,358.3,5835,0)
 ;;=185.^^28^386^18
 ;;^UTILITY(U,$J,358.3,5835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5835,1,3,0)
 ;;=3^185.
 ;;^UTILITY(U,$J,358.3,5835,1,4,0)
 ;;=4^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,5835,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,5836,0)
 ;;=187.9^^28^386^13
 ;;^UTILITY(U,$J,358.3,5836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5836,1,3,0)
 ;;=3^187.9
 ;;^UTILITY(U,$J,358.3,5836,1,4,0)
 ;;=4^MALE GENITAL CANCER
 ;;^UTILITY(U,$J,358.3,5836,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,5837,0)
 ;;=193.^^28^386^21
 ;;^UTILITY(U,$J,358.3,5837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5837,1,3,0)
 ;;=3^193.
 ;;^UTILITY(U,$J,358.3,5837,1,4,0)
 ;;=4^THYROID CANCER
 ;;^UTILITY(U,$J,358.3,5837,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,5838,0)
 ;;=195.0^^28^386^7
 ;;^UTILITY(U,$J,358.3,5838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5838,1,3,0)
 ;;=3^195.0
 ;;^UTILITY(U,$J,358.3,5838,1,4,0)
 ;;=4^HEAD/FACE/NECK CANCER
 ;;^UTILITY(U,$J,358.3,5838,2)
 ;;=^267306
 ;;^UTILITY(U,$J,358.3,5839,0)
 ;;=199.1^^28^386^15
 ;;^UTILITY(U,$J,358.3,5839,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5839,1,3,0)
 ;;=3^199.1
 ;;^UTILITY(U,$J,358.3,5839,1,4,0)
 ;;=4^METASTATIC CANCER
 ;;^UTILITY(U,$J,358.3,5839,2)
 ;;=^87705
 ;;^UTILITY(U,$J,358.3,5840,0)
 ;;=202.80^^28^386^12
 ;;^UTILITY(U,$J,358.3,5840,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5840,1,3,0)
 ;;=3^202.80
 ;;^UTILITY(U,$J,358.3,5840,1,4,0)
 ;;=4^LYMPHOMA
 ;;^UTILITY(U,$J,358.3,5840,2)
 ;;=^87701
 ;;^UTILITY(U,$J,358.3,5841,0)
 ;;=208.90^^28^386^9
 ;;^UTILITY(U,$J,358.3,5841,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5841,1,3,0)
 ;;=3^208.90
 ;;^UTILITY(U,$J,358.3,5841,1,4,0)
 ;;=4^LEUKEMIA w/o REMISSION
 ;;^UTILITY(U,$J,358.3,5841,2)
 ;;=^336874
 ;;^UTILITY(U,$J,358.3,5842,0)
 ;;=208.91^^28^386^8
 ;;^UTILITY(U,$J,358.3,5842,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5842,1,3,0)
 ;;=3^208.91
 ;;^UTILITY(U,$J,358.3,5842,1,4,0)
 ;;=4^LEUKEMIA w/ REMISSION
 ;;^UTILITY(U,$J,358.3,5842,2)
 ;;=^267576
 ;;^UTILITY(U,$J,358.3,5843,0)
 ;;=996.80^^28^387^1
 ;;
 ;;$END ROU IBDEI0CZ
